Studies that explore the efficacy and safety of JAK inhibitors for rheumatoid arthritis are among those we selected as most noteworthy in 2019. Also, at the top of the list, a study that shows glucocorticoids, not necessarily biologics, raise the infection risk after joint replacement surgery. Learn more in this slideshow.
Rheumatology Network Editorial Staff
There were some noteworthy achievements in rheumatology this year: A biosimilar was approved for rheumatoid arthritis, a workable treatment was discovered for systemic sclerosis lung disease, treatment guidelines were penned for JIA-related uveitis and more. In this slideshow, we highlight a few of these achievements.
In this slideshow, we review the year's most noteworthy new books in rheumatology as selected by BookAuthority.com. This is by no means a comprehensive list, but it offers a good look at the diverse selections of rheumatology books published this year.
Step therapy policies may be blocking timely access to care for rheumatology patients, finds a new report by Xcenda, an AmerisourceBergen company. The report finds that patients are more likely to be nonadherent or pay out of their own pocket for drugs. Learn more in this slideshow.
Xcenda, an AmerisourceBergen company, has just published a white paper that demonstrates the prevalence of step therapy and its potential negative impact on rheumatology patients. The authors of the report say the practice doesn’t always have the best interest of patents in mind and payers don't entirely disagree. Learn more in this report.
Treatment with interleukin (IL) inhibitors appear to be associated with an increased risk of serious infections, opportunistic infections and cancer in rheumatology patients, according to a systemic review and meta-analysis published in in JAMA Network Open this fall. This study was selected by Rheumatology Network as among the most noteworthy of 2019. Learn more in this slideshow.
In this month's rheumatoid arthritis quiz, we focus on contraception, a patient's preference for tapering and the self-management of flares.
In this month's psoriatic arthritis quiz, we revisit studies presented at the American College of Rheumatology annual meeting last month. Included here is one that highlights interesting trends in prescribing practices by physicians from different specialties. Which specialty is more likely to prescribe more medications?
The safety of live virus vaccines in patients receiving biologic therapies was confirmed in a study of 617 patients recently presented at the American College of Rheumatology annual meeting this month.
Even though senior patients with rheumatoid arthritis receive biologic therapies less often than patients who develop the condition early in life, a Japanese study presented this month at the ACR annual meeting, shows that patients 60 years and older can benefit from therapy just as much as younger patients.